immune-tolerance
(2)
Dan Baker
Dan Baker is a physician-scientist turned biotech founder who spent two decades at Johnson & Johnson's Janssen division helping bring immunology blockbusters Remicade, Simponi and Stelara to patients, before launching Brisbane-based Kira Biotech in 2019 as its founding CEO. Kira is developing KB312, a first-in-class antibody designed to selectively retrain the immune system rather than broadly suppress it, aimed at autoimmune diseases such as rheumatoid arthritis, lupus and type 1 diabetes. A rheumatologist who taught at the University of Pennsylvania for 18 years, Baker also advises drug-development organisations and serves as a healthcare venture partner.
Jason Cole
Jason F. Cole is the founding CEO and board member of Zag Bio, a Cambridge, Massachusetts biotech that launched in October 2025 with $80 million to develop thymus-targeted medicines for autoimmune diseases, starting with Type 1 diabetes. A lawyer by training with a J.D. from Columbia and an A.B. in Government from Dartmouth, Cole has spent more than two decades in biotech operations and finance. At bluebird bio he helped grow the company from roughly 100 to 1,200 employees, raised over $3.7 billion in equity financings, and helped deliver multiple first-in-class gene and cell therapies to patients. He most recently led SalioGen Therapeutics as CEO and Board Chair, and serves as Vice Chair of the MassBio board.